Crystal structure of rabbit muscle glycogen phosphorylase a in complex with a potential hypoglycaemic drug at 2.0 Å resolution

Biochimica et Biophysica Acta - Proteins and Proteomics

Volumn 1647, Issue 1-2, 2003, Pages 325-332

  Oikonomakos, Nikos G ^a   Chrysina, Evangelia D ^a   Kosmopoulou, Magda N ^a   Leonidas, Demetres D ^a  

^a INSTITUTE OF BIOLOGY   (Greece)

Author keywords

Glycogen metabolism; Glycogen phosphorylase; Indole 2 carboxamide; Inhibition; Type 2 diabetes; X ray structure

Indexed keywords

ANTIDIABETIC AGENT; CP 320626; CP 403700; ENZYME INHIBITOR; GLUCOSE; GLUCOSE DERIVATIVE; GLYCOGEN PHOSPHORYLASE; UNCLASSIFIED DRUG; AMIDE; INDOLE DERIVATIVE;

ALLOSTERISM; CATALYSIS; CONFERENCE PAPER; CONFORMATIONAL TRANSITION; CRYSTAL STRUCTURE; CRYSTALLOGRAPHY; DRUG MECHANISM; DRUG POTENCY; DRUG PROTEIN BINDING; ENZYME INHIBITION; PRIORITY JOURNAL; RABBIT; ANIMAL; ARTICLE; CHEMISTRY; CRYSTALLIZATION; ENZYME ACTIVE SITE; X RAY CRYSTALLOGRAPHY;

ORYCTOLAGUS CUNICULUS;

ALLOSTERIC REGULATION; AMIDES; ANIMALS; CATALYTIC DOMAIN; CRYSTALLIZATION; CRYSTALLOGRAPHY, X-RAY; ENZYME INHIBITORS; GLUCOSE; GLYCOGEN PHOSPHORYLASE, MUSCLE FORM; HYPOGLYCEMIC AGENTS; INDOLES; RABBITS;

EID: 0038650958     PISSN: 15709639     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1570-9639(03)00085-2     Document Type: Conference Paper

References (33)

1. Johnson L.N., Hajdu J., Acharya K.R., Stuart D.I., McLaughlin P.J., Oikonomakos N.G., Barford D. Glycogen phosphorylase b. Herve G. Allosteric Enzymes. 1989;81-127 CRC Press, Boca Raton, FL.
2. Newgard C.B., Hwang P.K., Fletterick R.J. The family of glycogen phosphorylases: structure and function. CRC Crit. Rev. Biochem. Mol. Biol. 24:1989;69-99.
3. Somsák L., Kovács L., Tóth M., Osz E., Szilágyi L., Györgydeák Z., Dinya Z., Docsa T., Tóth B., Gergely P. Synthesis of and a comparative study on the inhibition of muscle and liver glycogen phosphorylases by epimeric pairs of D-gluco- and D-xylopyranosylidene-spiro-(thio)hydantoins and N-(D-glucopyaranosyl) amides. J. Med. Chem. 44:2001;2843-2848.
4. Treadway J.L., Mendys P., Hoover D.J. Glycogen phosphorylase inhibitors for treatment of type 2 diabetes mellitus. Expert Opin. Investig. Drugs. 10:2001;439-454.
5. Oikonomakos N.G., Kosmopoulou M., Zographos S.E., Leonidas D.D., Chrysina E.D., Somsák L., Nagy V., Hadady Z., Docsa T., Tóth B., Gergely P. Binding of N-acetyl-N′-β-D-glucopyranosyl urea N-benzoyl-N′-β-D-glucopyranosyl urea to glycogen phosphorylase b: kinetic and crystallographic studies. Eur. J. Biochem. 269:2002;1684-1696.
6. Monod J., Wyman J., Changeux J.-P. On the nature of allosteric transitions: a plausible model. J. Mol. Biol. 12:1965;88-118.
7. Sprang S.R., Acharya K.R., Goldsmith E.J., Stuart D.I., Varvill K., Fletterick R.J., Madsen N.B., Johnson L.N. Structural changes in glycogen phosphorylase induced by phosphorylation. Nature. 336:1988;215-221.
8. Barford D., Johnson L.N. The allosteric transition of glycogen phosphorylase. Nature. 340:1989;609-616.
9. Barford D., Hu S.H., Johnson L.N. Structural mechanism for glycogen phosphorylase control by phosphorylation and AMP. J. Mol. Biol. 218:1991;233-260.
10. Sprang S.R., Withers S.G., Goldsmith E.J., Fletterick R.J., Madsen N.B. Structural basis for activation of glycogen phosphorylase b by adenosine monophosphate. Science. 254:1991;1367-1371.
11. Rath V.L., Ammirati M., LeMotte P.K., Fennell K.F., Mansour M.N., Danley D.E., Hynes T.R., Schulte G.K., Wasliko D.J., Pandit J. Activation of human liver glycogen phosphorylase by alteration of the secondary structure and packing of the catalytic core. Mol. Cell. 6:2000;139-148.
12. Johnson L.N. Glycogen phosphorylase: control by phosphorylation and allosteric effectors. FASEB J. 6:1992;2274-2282.
13. Johnson L.N., Lewis R.J. Structural basis for control by phosphorylation. Chem. Rev. 101:2001;2209-2242.
14. Hoover D.J., Lefkowitz-Snow S., Burgess-Henry J.L., Martin W.H., Armento S.J., Stock I.A., McPherson R.K., Genereux P.E., Gibbs E.M., Treadway J.L. Indole-2-carboxamide inhibitors of human liver glycogen phosphorylase. J. Med. Chem. 41:1998;2934-2938.
15. Oikonomakos N.G., Skamnaki V.T., Tsitsanou K.E., Gavalas N.G., Johnson L.N. A new allosteric site in glycogen phosphorylase b as a target for drug interactions. Structure. 8:2000;575-584.
16. Oikonomakos N.G., Zographos S.E., Skamnaki V.T., Archontis G. The 1.76 Å resolution crystal structure of glycogen phosphorylase b complexed with glucose, and CP320626, a potential antidiabetic drug. Bioorg. Med. Chem. 10:2002;1313-1319.
17. Rath V.L., Ammirati M., Danley D.E., Ekstrom J.L., Gibbs E.M., Hynes T.R., Mathiowetz A.M., McPherson R.K., Olson T.V., Treadway J.L., Hoover D.J. Human liver glycogen phosphorylase inhibitors bind at a new allosteric site. Chem. Biol. 7:2000;677-682.
18. Christopoulos Allosteric binding sites on cell-surface receptors: novel targets for drug discovery. Nat. Rev., Drug Discov. 1:2002;198-210.
19. Oikonomakos N.G., Tsitsanou K.E., Zographos S.E., Skamnaki V.T., Goldmann S., Bischoff H. Allosteric inhibition of glycogen phosphorylase a by the potential antidiabetic drug 3-isopropyl 4-(2-chlorophenyl)-1,4-dihydro-1- ethyl-2-methyl-pyridine-3,5,6-tricarboxylate. Protein Sci. 8:1999;1930-1945.
20. Otwinowski Z., Minor W. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 276:1997;307-326.
21. Brünger A.T. X-PLOR Version 3.1. A System for X-ray Crystallography and NMR. 1992;Yale Univ. Press, New Haven.
22. Read R.J. Improved coefficients for map calculation using partial structures with errors. Acta Crystallogr. A42:1986;140-149.
23. Jones T.A., Zou J.Y., Cowan S.W., Kjeldgaard M. Improved methods for the building of protein models in electron density maps and the location of errors in these models. Acta Crystallogr. A47:1991;110-119.
24. Luzatti V. Traitement statistique des erreurs dans la determination des structure crystallines. Acta Crystallogr. 5:1952;802-810.
25. Laskowski R.A., MacArthur M.W., Moss D.S., Thornton J.M. PROCHECK: a programme to check the stereochemical quality of protein structures. J. Appl. Crystallogr. 26:1993;283-291.
26. Collaborative computational project, number 4, the CCP4 suite: programs for protein crystallography. Acta Crystallogr. D50:1994;760-763.
27. Oikonomakos N.G., Zographos S.E., Skamnaki V.T., Tsitsanou K.E., Johnson L.N. Flavopiridol inhibits glycogen phosphorylase by binding at the inhibitor site. J. Biol. Chem. 275:2000;34566-34573.
28. Martin J.L., Veluraja K., Johnson L.N., Fleet G.W.J., Ramsden N.G., Bruce I., Oikonomakos N.G., Papageorgiou A.C., Leonidas D.D., Tsitoura H.S. Glucose analogue inhibitors of glycogen phosphorylase: the design of potential drugs for diabetes. Biochemistry. 30:1991;10101-10116.
29. Tsitsanou K.E., Skamnaki V.T., Oikonomakos N.G. Structural basis of the synergistic inhibition of glycogen phosphorylase a by caffeine and a potential antidiabetic drug. Arch. Biochem. Biophys. 384:2000;245-254.
30. Zographos S.E., Oikonomakos N.G., Tsitsanou K.E., Leonidas D.D., Chrysina E.D., Skamnaki V.T., Bischoff H., Goldman S., Schram M., Watson K.A., Johnson L.N. The structure of glycogen phosphorylase b with an alkyl-dihydropyridine-dicarboxylic acid compound, a novel and potent inhibitor. Structure. 5:1997;1413-1425.
31. Oikonomakos N.G., Kontou M., Zographos S.E., Watson K.A., Johnson L.N., Bichard C.J.F., Fleet G.W.J., Acharya K.R. N-acetyl-β-D- glucopyranosylamine: a potent T state inhibitor of glycogen phosphorylase. A comparison with α-D-glucose. Protein Sci. 4:1995;2469-2477.
32. Kraulis P. MOLSCRIPT: a program to produce both detailed and schematic plots of protein structures. J. Appl. Crystallogr. 24:1991;946-950.
33. Merritt E.A., Bacon D.J. Raster3D: photorealistic molecular graphics. Methods Enzymol. 277:1997;505-524.